European equities traded in the US as American depositary receipts were tracking lower late Wednesday, declining 0.38% to 1,481.07 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and internet advertising firm Criteo (CRTO), which rose 4.2% and 2.4%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and oil and gas company TotalEnergies (TTE), which were up 1.7% and 1.2%, respectively.
The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical firm DBV Technologies (DBVT), which fell 3.6% and 3.2%, respectively. They were followed by consumer goods company Unilever (UL) and semiconductor company Sequans Communications (SQNS), which were down 1.3% and 1%, respectively.
From the UK and Ireland, the gainers were led by biotech company Autolus Therapeutics (AUTL) and biopharmaceutical firm Bicycle Therapeutics (BCYC), which increased 4.2% and 3.6%, respectively. Biopharmaceutical firms Mereo BioPharma Group (MREO) and Verona Pharma (VRNA) rose 3.5% and 2.8%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and financial services company Lloyds Banking Group (LYG), which lost 9.1% and 5.1% respectively. They were followed by utilities company National Grid (NGG) and biotech company Trinity Biotech (TRIB), which dropped 4.4% and 3% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。